Five Prime Therapeutics develops innovative protein and antibody therapeutics from its San Francisco base. The company is advancing a pre-clinical stage therapeutic candidate for the treatment of multiple sclerosis (MS). It received $1M in funding from Fast Forward, LLC, a subsidiary of the National Multiple Sclerosis Society, to support that program. The funds will enable pre-clinical testing of a proprietary biological molecule discovered at Five Prime that targets specific cells of the innate immune system. Recent research cited in the announcement suggests the innate immune system contributes to disease activity in both relapsing remitting and progressive forms of MS. The company’s near-term plan is to use the grant to complete the described pre-clinical testing.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

May 2010